Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Affinivax

Request full access

Biotechnology company developing a novel conjugation technology

Cambridge, United StatesFounded 2014Biotech & Life Sciences

About Affinivax

Affinivax is a clinical-stage biotechnology company specializing in the development of next-generation vaccines and immunotherapies. The company operates in the healthcare and biotechnology market, focusing on infectious and immune-mediated diseases. Affinivax's core technology, the Multiple Antigen Presenting System (MAPS), enables the high-affinity binding of polysaccharides and proteins in a single vaccine. This unique approach induces a broad and protective B and T cell immune response, offering novel preventive and therapeutic solutions. The company's lead vaccine program targets Streptococcus pneumoniae, a significant cause of pneumonia and other serious infections. Affinivax generates revenue through partnerships, grants, and potential future sales of its proprietary vaccines. The company serves healthcare providers, patients, and global health organizations.

Source: Dealroom company data

Affinivax in the Cambridge ecosystem

Live from Dealroom

The Affinivax office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Bill & Melinda Gates Foundation

Series A2 investors entered at this stage

  • Viking Global Investors
  • Bain Capital Life Sciences

Series B and later11 investors entered at this stage

Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$11M

7 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Affinivax on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.